|
|
|
|
 |
|
 |
|
| Ranks among the top ten players in the overall market, Among top 5 in Generics |
| Strong position in the anti-infectives segment with a well established portfolio of products and market leading positions |
| 75 products in 185 pharmaceutical forms |
|
| 68 Branded Generic Products, 174 presentation forms |
| 7 Licensed Products, 11 presentation forms |
|
|
|
 |
|
| One of the first API production in Turkey |
| Currently, two important APIs, Potassium Clavulanate and Cefuroxime Axetil, are produced within the Group |
| Potassium Clavulanate is the API behind Deva's top selling drug Amoklavin |
| Cefuroxime Axetil is the API behind Deva's second best selling drug Cefaks |
|
|
Web Site: www.depapharm.com.tr |
|
|
 |
|
| Large product portfolio including 60 registered products with over 100 presentation forms |
| Second largest player in the market in 2005, with a market share of 10% in terms of revenues |
|
|
Web Site: www.vetas.com.tr |
|
|
|
 |
|
|
